R-Pharm and AbbVie to start supplying new hepatitis C drug for state needs in Russia

17 May 2018

R-Pharm, one of Russia’s leading drugmakers, has won a tender in Russia for the supply of Viekira Pak (ombitasvir, paritaprevir, ritonarvir tablets, dasabuvir tablets), a drug for the treatment of hepatitis C for state needs this year, according to recent statements of the company and senior officials of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.

The drug is currently produced in Europe by the USA’s AbbVie (NYSE: ABBV) and was included in the list of vital and essential drugs (VED) in Russia in 2017, after Russia’s President Vladimir Putin promised to support R-Pharm’s business by the beginning purchases of drugs produced by the company for state needs.

The value of the contract is 413 million roubles (~$7 million). Under the terms of the deal, up to 120,400 packs of Viekira Pak will be supplied to the Russian state this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK